Literature DB >> 15525549

Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus.

Jens Juul Holst1, Carolyn F Deacon.   

Abstract

Proof-of-concept for the efficacy of a glucagon-like peptide 1 (GLP-1)-based therapy of patients with type 2 diabetes was provided in 2002 by means of prolonged continuous subcutaneous infusion of native GLP-1. Since then, several long-acting analogues of GLP-1, as well as inhibitors of dipeptidyl peptidase IV, the enzyme that rapidly inactivates endogenous GLP-1, have demonstrated efficacy in long term clinical trials.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15525549     DOI： 10.1016/j.coph.2004.08.005

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN： 1471-4892            Impact factor:   5.547


  22 in total

Review 1.  [Update on the latest family of oral drugs marketed for the treatment of type 2 diabetes: DPP-4 inhibitors. Contributions with respect to other families of oral antidiabetic agents].

Authors:  Fernando Alvarez Guisasola
Journal:  Aten Primaria       Date:  2010-09       Impact factor: 1.137

Review 2.  Prandial glucose regulation in the glucose triad: emerging evidence and insights.

Authors:  Paul Beisswenger; Robert J Heine; Lawrence A Leiter; Alan Moses; Jaakko Tuomilehto
Journal:  Endocrine       Date:  2004-12       Impact factor: 3.633

Review 3.  Food protein-derived bioactive peptides in management of type 2 diabetes.

Authors:  Prasad Patil; Surajit Mandal; Sudhir Kumar Tomar; Santosh Anand
Journal:  Eur J Nutr       Date:  2015-07-08       Impact factor: 5.614

Review 4.  Gut microbes, diet, and cancer.

Authors:  Meredith A J Hullar; Andrea N Burnett-Hartman; Johanna W Lampe
Journal:  Cancer Treat Res       Date:  2014

5.  Administration of a dipeptidyl peptidase IV inhibitor enhances the intestinal adaptation in a mouse model of short bowel syndrome.

Authors:  Manabu Okawada; Jens J Holst; Daniel H Teitelbaum
Journal:  Surgery       Date:  2011-06-30       Impact factor: 3.982

6.  Influence of selective fluorination on the biological activity and proteolytic stability of glucagon-like peptide-1.

Authors:  He Meng; Subrahmanian Tarakkad Krishnaji; Martin Beinborn; Krishna Kumar
Journal:  J Med Chem       Date:  2008-11-27       Impact factor: 7.446

7.  Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects.

Authors:  Jerry R Greenfield; I Sadaf Farooqi; Julia M Keogh; Elana Henning; Abdella M Habib; Anthea Blackwood; Frank Reimann; Jens J Holst; Fiona M Gribble
Journal:  Am J Clin Nutr       Date:  2008-12-03       Impact factor: 7.045

8.  Molecular dynamics and free energy studies of chirality specificity effects on aminobenzo[a]quinolizine inhibitors binding to DPP-IV.

Authors:  Cui Wei; Liang Desheng; Gao Jian; Luo Fang; Geng Lingling; Ji Mingjuan
Journal:  J Mol Model       Date:  2012-11-15       Impact factor: 1.810

9.  Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA(1c) level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic mice.

Authors:  Akiko Matsuyama-Yokono; Atsuo Tahara; Ryosuke Nakano; Yuka Someya; Masahiko Hayakawa; Masayuki Shibasaki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-09-02       Impact factor: 3.000

10.  Molecular docking and 3D-QSAR studies on beta-phenylalanine derivatives as dipeptidyl peptidase IV inhibitors.

Authors:  Yan-Ke Jiang
Journal:  J Mol Model       Date:  2010-01-13       Impact factor: 1.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.